Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be higher compared to other studies. This lead to a prospective observational study to look at the incidence and severity of skin reactions following routine clinical application of Ametop.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: KK Women's and Children's Hospital
• Treatments: Tetracaine

Criteria

Inclusion Criteria:

• All paediatric patients presenting for surgery from August 2014 to May 2015 who have had Ametop applied prior to intravenous cannulation.

Exclusion Criteria:

• Any patient who did not have Ametop applied or have an intravenous cannula in situ.